Targeted α-Therapy Using 225 Ac Radiolabeled Single-Domain Antibodies Induces Antigen-Specific Immune Responses and Instills Immunomodulation Both Systemically and at the Tumor Microenvironment
Journal of Nuclear Medicine · 2023-05 · 64 (5) · 751-758
DOI: 10.2967/jnumed.122.264752 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 13.04.2023. Verfasst von Thomas Ertveldt und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, Laboratory for Molecular and Cellular Therapy, Vrije Universiteit Brussel, Brussels, Belgium. Hauptthemen laut MEDLINE: Single-Domain Antibodies, Melanoma, Experimental. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 28 Literaturangaben.
Abstract (Originalsprache)
Targeted radionuclide therapy (TRT) using targeting moieties labeled with α-particle-emitting radionuclides (α-TRT) is an intensely investigated treatment approach as the short range of α-particles allows effective treatment of local lesions and micrometastases. However, profound assessment of the immunomodulatory effect of α-TRT is lacking in literature.
Methods
Using flow cytometry of tumors, splenocyte restimulation, and multiplex analysis of blood serum, we studied immunologic responses ensuing from TRT with an antihuman CD20 single-domain antibody radiolabeled with 225Ac in a human CD20 and ovalbumin expressing B16-melanoma model.
Results
Tumor growth was delayed with α-TRT and increased blood levels of various cytokines such as interferon-γ, C-C motif chemokine ligand 5, granulocyte-macrophage colony-stimulating factor, and monocyte chemoattractant protein-1. Peripheral antitumoral T-cell responses were detected on α-TRT. At the tumor site, α-TRT modulated the cold tumor microenvironment (TME) to a more hospitable and hot habitat for antitumoral immune cells, characterized by a decrease in protumoral alternatively activated macrophages and an increase in antitumoral macrophages and dendritic cells. We also showed that α-TRT increased the percentage of programmed death-ligand 1 (PD-L1)-positive (PD-L1pos) immune cells in the TME. To circumvent this immunosuppressive countermeasure we applied immune checkpoint blockade of the programmed cell death protein 1-PD-L1 axis. Combination of α-TRT with PD-L1 blockade potentiated the therapeutic effect, however, the combination aggravated adverse events. A long-term toxicity study revealed severe kidney damage ensuing from α-TRT.
Conclusion
These data suggest that α-TRT alters the TME and induces systemic antitumoral immune responses, which explains why immune checkpoint blockade enhances the therapeutic effect of α-TRT. However, further optimization is warranted to avoid adverse events.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Sciences, Laboratory for Molecular and Cellular Therapy, Vrije Universiteit Brussel, Brussels, Belgium.
- Department of Medical Imaging, In Vivo Cellular and Molecular Imaging Laboratory, Vrije Universiteit Brussel, Brussels, Belgium.
- Department of Hematology and Immunology, Myeloma Center Brussels, Vrije Universiteit Brussel, Brussels, Belgium.
- European Commission, Joint Research Centre, Directorate for Nuclear Safety and Security, Karlsruhe Institut, Germany; and.
- Department of Nuclear Medicine, UZ Brussel, Brussels, Belgium.
- Department of Biomedical Sciences, Laboratory for Molecular and Cellular Therapy, Vrije Universiteit Brussel, Brussels, Belgium; Karine.Breckpot@vub.be.
Zitieren
APA
Ertveldt, T., Krasniqi, A., Ceuppens, H., Puttemans, J., Dekempeneer, Y., Jonghe, K., Mey, W., Lecocq, Q., Vlaeminck, Y., Awad, R. M., Goyvaerts, C., Veirman, K., Morgenstern, A., Bruchertseifer, F., Keyaerts, M., Devoogdt, N., D'Huyvetter, M., & Breckpot, K. (2023). Targeted α-Therapy Using 225 Ac Radiolabeled Single-Domain Antibodies Induces Antigen-Specific Immune Responses and Instills Immunomodulation Both Systemically and at the Tumor Microenvironment. Journal of Nuclear Medicine, 64(5), 751-758. https://doi.org/10.2967/jnumed.122.264752
Vancouver
Ertveldt T, Krasniqi A, Ceuppens H, Puttemans J, Dekempeneer Y, Jonghe K, et al. Targeted α-Therapy Using 225 Ac Radiolabeled Single-Domain Antibodies Induces Antigen-Specific Immune Responses and Instills Immunomodulation Both Systemically and at the Tumor Microenvironment. Journal of Nuclear Medicine. 2023;64(5):751-758. doi:10.2967/jnumed.122.264752
BibTeX
@article{Ertveldt2023,
author = {Ertveldt, Thomas and Krasniqi, Ahmet and Ceuppens, Hannelore and Puttemans, Janik and Dekempeneer, Yana and Jonghe, Kevin De and Mey, Wout de and Lecocq, Quentin and Vlaeminck, Yannick De and Awad, Robin Maximilian and Goyvaerts, Cleo and Veirman, Kim De and Morgenstern, Alfred and Bruchertseifer, Frank and Keyaerts, Marleen and Devoogdt, Nick and D'Huyvetter, Matthias and Breckpot, Karine},
title = {Targeted α-Therapy Using 225 Ac Radiolabeled Single-Domain Antibodies Induces Antigen-Specific Immune Responses and Instills Immunomodulation Both Systemically and at the Tumor Microenvironment},
journal = {Journal of Nuclear Medicine},
year = {2023},
volume = {64},
number = {5},
pages = {751--758},
doi = {10.2967/jnumed.122.264752}
}
EUVIMED